SUBSCRIBE
SUBSCRIBE
News   Drug Development

BioDelivery Sciences International Anticipates Announcing Phase III BEMA Fentanyl Efficacy Data In April

February 8, 2007 | 
1 min read
MORRISVILLE, N.C.--(BUSINESS WIRE)--BioDelivery Sciences International, Inc. (Nasdaq:BDSI) plans to report Phase III data in April, regarding the efficacy of BEMA Fentanyl in the treatment of breakthrough pain in cancer patients.
Clinical research Phase 3
MORE ON THIS TOPIC
Target, miss the target, target shooting, dart, correct decisions, bow and arrow, dart on target, hits and misses (3d illustration)
Neuroscience
Ono cans 2 endocannabinoid drug studies after quintuple Phase 2 failure
October 29, 2026
 · 
1 min read
 · 
Annalee Armstrong
Insights
Stability, speed and strategy: Inside Australia’s early‑stage edge
October 29, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Target with three arrows in the bullseye. Close-up version. Vintage style vector illustration.
Cancer
Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout
October 28, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Vector of a smart business man pushing a sphere uphill leading the race against a slower businessman pushing a box. Winning strategy concept
Diabetes
Lilly’s retatrutide trounces Novo’s Ozempic in diabetes, weight loss
October 28, 2026
 · 
3 min read
 · 
Annalee Armstrong